Additionally, a clinical trial studying the treatment of MG patients with the BAFF/APRIL (a proliferation‐inducing ligand) dual‐target inhibitor telitacicept further supports this hypothesis. This evidence concerns the gene TNFSF13B and myasthenia gravis.